Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Resiquimod in Early Stage CTCL
NCT01676831Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Feb 2012
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of resiquimod in cutaneous T-cell lymphoma (CTCL), sponsored by Abramson Cancer Center. Started Feb 2012; status: completed.
02
Drugs
resiquimod
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT01676831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01676831.